Literature DB >> 23109779

Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.

Raj Sahu1, Duraisamy Balaguru, Vandana Thapar, Ikram Haque, Chi Pham-Peyton, J Timothy Bricker.   

Abstract

Conivaptan is a nonspecific arginine vasopressin receptor antagonist that has been used as therapy in adults who have hypervolemic hyponatremia due to congestive heart failure. Its use in children with congestive heart failure has not been reported. We describe the use of conivaptan in a 4-month-old infant girl with severe hypervolemic hyponatremia and heart failure. A therapeutic weight-based dose was extrapolated from the adult dose. Conivaptan therapy was administered for 48 hours, after which the patient recovered from her hyponatremia without untoward effects. Arginine vasopressin receptor antagonists such as conivaptan may be useful as therapy for hyponatremia associated with heart failure. Further studies are required before conivaptan can be recommended for routine use in children.

Entities:  

Keywords:  Antidiuretic agents/therapeutic use; conivaptan; heart failure/complications; hyponatremia/drug therapy; receptors, vasopressin/antagonists & inhibitors; risk factors; sodium/blood; treatment outcome

Mesh:

Substances:

Year:  2012        PMID: 23109779      PMCID: PMC3461679     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  9 in total

1.  Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure.

Authors:  Louise Balling; Morten Schou; Lars Videbæk; Per Hildebrandt; Henrik Wiggers; Finn Gustafsson
Journal:  Eur J Heart Fail       Date:  2011-07-09       Impact factor: 15.534

Review 2.  Vasopressin antagonism in heart failure.

Authors:  Steven R Goldsmith; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2005-10-21       Impact factor: 24.094

Review 3.  Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Authors:  Natig Gassanov; Nasser Semmo; Mariam Semmo; Amir M Nia; Uwe Fuhr; Fikret Er
Journal:  Eur J Clin Pharmacol       Date:  2011-02-17       Impact factor: 2.953

4.  Hyponatremia treatment guidelines 2007: expert panel recommendations.

Authors:  Joseph G Verbalis; Stephen R Goldsmith; Arthur Greenberg; Robert W Schrier; Richard H Sterns
Journal:  Am J Med       Date:  2007-11       Impact factor: 4.965

5.  Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.

Authors:  Djillali Annane; Guy Decaux; Neila Smith
Journal:  Am J Med Sci       Date:  2009-01       Impact factor: 2.378

Review 6.  Vasopressin and vasopressin receptor antagonists in heart failure.

Authors:  Gerard Oghlakian; Marc Klapholz
Journal:  Cardiol Rev       Date:  2009 Jan-Feb       Impact factor: 2.644

7.  Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.

Authors:  Pornpimol Rianthavorn; Joan P Cain; Martin A Turman
Journal:  Pediatr Nephrol       Date:  2008-04-24       Impact factor: 3.714

8.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

9.  Conivaptan: a step forward in the treatment of hyponatremia?

Authors:  Su Su Hline; Phuong-Truc T Pham; Phuong-Thu T Pham; May H Aung; Phuong-Mai T Pham; Phuong-Chi T Pham
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

  9 in total
  2 in total

1.  Novel Use of Tolvaptan in a Pediatric Patient With Congestive Heart Failure Due to Duchenne Muscular Dystrophy and Congenital Adrenal Hyperplasia.

Authors:  Sarah A Sami; Brady S Moffett; Melissa L Karlsten; Antonio G Cabrera; Jack F Price; William J Dreyer; Susan W Denfield; Aamir Jeewa
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Sep-Oct

2.  Tolvaptan increases serum sodium in pediatric patients with heart failure.

Authors:  Rebecca B Regen; Ashley Gonzalez; Kasey Zawodniak; David Leonard; Raymond Quigley; Aliessa P Barnes; Joshua D Koch
Journal:  Pediatr Cardiol       Date:  2013-03-05       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.